Track the Whitehawk Therapeutics, Inc. stock price and the full directors' dealings record of the company, a listed equity based in United States. Shares are listed on the US market, under the supervision of SEC (Form 4). Market capitalisation: €2.5bn. The latest transaction was reported on 30 July 2026 (Attribution). Among the most active insiders: Lennon David James. Every trade is accessible without an account.
18
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€2m
11 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Whitehawk Therapeutics, Inc. Strong Buy (bullish), based on 12 analysts. Average price target: US$62.05.
38Σ signal
Buys n/a€2m Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
Whitehawk Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for autoimmune diseases. It employs innovative approaches to target the underlying mechanisms of these conditions.